| Full text | |
| Author(s): Show less - |
Silva, Eliane P.
;
Trentini, Monalisa
;
Rodriguez, Dunia
;
Kanno, Alex I.
;
Gomes, Filumena M. S.
;
Valente, Maria H.
;
Trufen, Carlos E. M.
;
Yamamoto, Lais S.
;
Januzzi, Arthur D.
;
Cunegundes, Priscila S.
;
Palacios, Ricardo
;
Souza, Renan P.
;
Raw, Isaias
;
Leite, Luciana C. C.
;
Dias, Waldely O.
Total Authors: 15
|
| Document type: | Journal article |
| Source: | FRONTIERS IN IMMUNOLOGY; v. 15, p. 12-pg., 2024-12-04. |
| Abstract | |
Background Pertussis continues to pose a significant threat despite the availability of effective vaccines. The challenge lies in the vulnerability of infants who have not yet completed their vaccination schedule and in adolescents and adults becoming potential disease carriers.Methods We evaluated the seroprevalence of pertussis immunity in a cohort of 1,500 healthy Brazilian volunteers. Next, we explored the potential restoration of waning pertussis immunity by administering booster doses of wP, aP or Plow (an economically viable and low reactogenic vaccine in development at Butantan) using a mouse model.Findings The mean anti-PT IgG levels in the Brazilian volunteers was 39.4 IU/mL. Notably, individuals <= 19 years exhibited higher IgG values compared to older age groups (>= 20 y). Overall, 8.4% of the samples displayed indications of recent or current contact/infection, with IgG levels surpassing 120 IU/mL, particularly in the 15-19 years age group. IgM values were also increased in the 10-19 years age group. Potential recovery of pre-existing but waning immunity investigated in mice, showed that boosting with wP induced higher antibody titers than aP or Plow. Notably, aP and Plow boosts prompted superior effector and memory cell responses from both B and T cells. Upon challenge with B. pertussis, aP or Plow boost provided greater protection as compared to wP.Interpretations Pertussis appears to circulate predominantly among adolescents and young adults. Insights from the mouse model indicate that immunity can be restored with booster doses. Boosting immunity in non-targeted groups could prevent the dissemination of pertussis to infants. (AU) | |
| FAPESP's process: | 17/24832-6 - Development of vaccines based on recombinant BCG: Tuberculosis, Pertussis, Pneumococcus and Schistosoma |
| Grantee: | Luciana Cezar de Cerqueira Leite |
| Support Opportunities: | Research Projects - Thematic Grants |
| FAPESP's process: | 20/14443-5 - Conjugation of antigens to the surface of BCG vaccine: application of the avidin-biotin system |
| Grantee: | Lais Sayuri Yamamoto |
| Support Opportunities: | Scholarships in Brazil - Master |
| FAPESP's process: | 19/06454-0 - Evaluation of BCG expressing adjuvant LTAK63 in a humanized mouse model as a therapeutic vaccine for Tuberculosis |
| Grantee: | Monalisa Martins Trentini |
| Support Opportunities: | Scholarships in Brazil - Post-Doctoral |
| FAPESP's process: | 21/14376-9 - Optimization of SARS-CoV-2 antigen production in Expi293 cell culture aiming OMV-based vaccine generation |
| Grantee: | Arthur Daniel Januzzi |
| Support Opportunities: | Scholarships in Brazil - Master |